That changed in July 2026 when Medicare launched the glucagon-like peptide-1 (GLP-1) Bridge Program, giving eligible beneficiaries access to medications like Wegovy and Zepbound with costs as low as $50/month for eligible beneficiaries, subject to program terms and eligibility
We've got data and (some) answers: Join the conversation
Later complications include anemia and neuropathy
While still largely experimental, gene therapy represents the potential for one-time treatments that produce lasting results without ongoing application
When the interventional cardiologist guides the Rotablator to the blockage, it begins to rotate, going as fast as 190,000 rpm
Ipamorelins selectivity rests on foundational pharmacology : mechanism-defining work that is robust for what it claims (a clean GH-secretagogue profile) but is not an efficacy trial for any body-composition endpoint